Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution agreement for Genesis products

16 Jul 2009 07:00

RNS Number : 7478V
Omega Diagnostics Group PLC
16 July 2009
 



AIM: ODX

Omega Diagnostics Group PLC ('Omega')

UK Distribution agreement for Genesis products 

Omega, the AIM listed medical diagnostics company, announces that its UK-based subsidiary, Genesis Diagnostics Ltd ('Genesis') has signed an exclusive distribution agreement with Biohit Healthcare Ltd ('Biohit'), the UK-based subsidiary of Biohit Oyj, a Finnish public company which develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Biohit will take on the UK distribution and servicing of the Genesis product range using their UK-wide sales force and will offer complete coverage of the UK NHS hospital network. Both companies are committed to maintaining and improving upon the high level of customer service provided by Genesis. Biohit already services many current Genesis customers and the customer base is expected to expand as a result of this agreement.

Andrew Shepherd, Chief Executive of Omega, said, "The synergy between Genesis and Biohit is clear in that both companies service the same clinical laboratory market with complementary products. The UK market for clinical diagnostic products is highly competitive and we need to have a full scale sales force that can operate across the UK and increase our business base going forward. Using Biohit provides us with access to a much enlarged customer base and allows our resources to be focussed on other growth areas in the UK and beyond."

 

Richard Vaughton, Managing Director of Biohit commented, "The addition of Genesis products enhances the offering to our current customer base and helps focus our sales drive in the clinical laboratory market. We look forward to providing an excellent service to existing Genesis customers, many of whom we are familiar with, and to winning many new customers."

Further enquiries:

Omega Diagnostics Group PLC:

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel : 020 7397 8900

Nick Wells, Andy Roberts, Elizabeth Bowman

ebowman@cenkos.com

Walbrook PR Limited

Tel : 020 7933 8787

Paul McManus

Mob : 07980 541 893

paul.mcmanus@walbrookpr.com

Information on Biohit Oyj

Biohit Oyj, a Finnish Public company, develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Established in 1988, Biohit Oyj is headquartered in Finland. Biohit has subsidiaries in FranceGermany, the UKRussiaChinaJapan and the USA. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit Oyj had net sales of 35.1M euros in 2008 and employed 370 personnel. 

Geographically sales are split as follows: Europe: 55.6%North & South America 18.1%Asia 11.5%Other Countries 14.8%

Biohit's shares (BIOBV) are quoted on NASDAQ OMX Helsinki. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBLGDRBBBGGCU
Date   Source Headline
10th Apr 20187:00 amRNSStrategic Review of operations and Trading Update
12th Jan 201812:14 pmRNSHolding(s) in Company
21st Dec 20177:00 amRNSAllersys® CE-Mark
14th Dec 20177:01 amRNSCEO succession
14th Dec 20177:00 amRNSInterim results
29th Nov 20177:00 amRNSVISITECT® CD4 CE-Mark
1st Nov 20177:00 amRNSChange of Registered Office
23rd Oct 20177:00 amRNSTrading Update and Notice of Interim Results
18th Oct 20179:00 amRNSPDMR Participation in SAYE Scheme
16th Oct 20177:00 amRNSUS Supply Agreement
10th Oct 20177:00 amRNSHolding(s) in Company
5th Sep 20172:07 pmRNSExercise of Options and Total Voting Rights
29th Aug 201711:51 amRNSResult of AGM
18th Jul 201710:35 amRNSResult of General Meeting
6th Jul 201711:56 amRNSSale and leaseback of building owned by Omega GmbH
30th Jun 201712:13 pmRNSResult of Proposed Fundraising
30th Jun 20177:01 amRNSProposed Fundraising
30th Jun 20177:00 amRNSFinal Results
25th Apr 20177:00 amRNSTrading Update and Notice of Results
21st Apr 201712:41 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSVISITECT® Malaria CE-Mark & Indian FDA inspection
7th Mar 20178:45 amRNSHolding(s) in Company
27th Feb 201712:52 pmRNSHolding(s) in Company
27th Jan 20177:00 amRNSUpdate on discussions with IDS
11th Jan 20177:00 amRNSISO accreditation for manufacturing facility
29th Nov 20167:15 amRNSHardman Research: Food intolerance driving growth
24th Nov 20167:52 amRNSHolding(s) in Company
21st Nov 20167:00 amRNSHalf-year Report
31st Oct 20167:15 amRNSHardman Research: Diagnosing growth opportunities
17th Oct 20167:00 amRNSTrading Update and Notice of Interim Results
10th Aug 201612:22 pmRNSResult of AGM
2nd Aug 20167:00 amRNSR&D Grant Funding
4th Jul 20168:18 amRNSHolding(s) in Company
1st Jul 201611:48 amRNSHolding(s) in Company
27th Jun 20167:00 amRNSFinal Results
9th Jun 20169:07 amRNSHolding(s) in Company
21st Apr 20167:00 amRNSTrading Update & Notice of Results
8th Feb 20168:22 amRNSHolding(s) in Company
4th Dec 20154:25 pmRNSHolding(s) in Company
3rd Dec 201512:28 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSHalf Yearly Report
26th Oct 20157:00 amRNSTrading Update and Notice of Interim Results
30th Sep 20159:07 amRNSGrant of Options
7th Sep 20151:21 pmRNSResult of AGM
7th Jul 20157:00 amRNSFinal Results
5th Jun 201510:01 amRNSHolding(s) in Company
1st Jun 20157:00 amRNSDevelopment Update - Visitect® CD4 and Allergy
27th Apr 20157:00 amRNSBoard Appointment
15th Apr 20157:00 amRNSTrading update and Notice of Results
1st Dec 201410:37 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.